Naltrexone Implant for Opioid Use Disorder.  Edinoff AN, Nix CA, Orellana CV, StPierre SM, Crane EA, Bulloch BT, Cornett EM, Kozinn RL, Kaye AM, Murnane KS, Kaye AD.  Neurol Int. 2021 Dec 30;14(1):49-61. doi: 10.3390/neurolint14010004....

'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.  Brenna IH, Marciuch A, Birkeland B, Veseth M, Røstad B, Løberg EM, Solli KK, Tanum L, Weimand B.  J Subst Abuse ...

Opioid antagonism modulates wanting-related frontostriatal connectivity.  Soutschek A, Weber SC, Kahnt T, Quednow BB, Tobler PN.  Elife. 2021 Nov 11;10:e71077. doi: 10.7554/eLife.71077. PMID: 34761749; PMCID: PMC8598157. https://www.n...

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.  Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Ponce Terashima J, McCarty D, Jacobs P, Korthuis PT.&...

Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up Gaulen, Zhanna et al. Journal of Substance Abuse Treatment, Volume 0, Issue 0, 1086...

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.  Roache, J.D., Pavlicova, M., Campbell, A., Choo...